GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (FRA:LWB) » Definitions » Shiller PE Ratio

Mesoblast (FRA:LWB) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast Shiller PE Ratio Historical Data

The historical data trend for Mesoblast's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Shiller PE Ratio Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.53 0.57

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 0.57 - - -

Competitive Comparison of Mesoblast's Shiller PE Ratio

For the Biotechnology subindustry, Mesoblast's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mesoblast's Shiller PE Ratio falls into.



Mesoblast Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mesoblast's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Mesoblast's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Mesoblast Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 -0.162 98.352 -0.208
201412 -0.067 99.002 -0.086
201503 -0.061 99.187 -0.078
201506 -0.078 99.838 -0.099
201509 -0.033 100.302 -0.042
201512 -0.054 100.673 -0.068
201603 -0.038 100.488 -0.048
201606 0.114 100.859 0.143
201609 -0.044 101.602 -0.055
201612 -0.047 102.159 -0.058
201703 -0.022 102.624 -0.027
201706 -0.053 102.809 -0.065
201709 -0.013 103.460 -0.016
201712 0.023 104.110 0.028
201803 -0.034 104.574 -0.041
201806 -0.036 104.945 -0.043
201809 -0.033 105.410 -0.040
201812 -0.042 105.967 -0.050
201903 -0.042 105.967 -0.050
201906 -0.035 106.617 -0.041
201909 -0.009 107.174 -0.011
201912 -0.039 107.917 -0.046
202003 -0.024 108.289 -0.028
202006 -0.051 106.246 -0.061
202009 -0.034 107.917 -0.040
202012 -0.034 108.846 -0.039
202103 -0.035 109.496 -0.040
202106 -0.026 110.332 -0.030
202109 -0.028 111.168 -0.032
202112 -0.034 112.654 -0.038
202203 -2.824 115.069 -3.102
202206 9.543 117.112 10.300
202209 -0.023 119.248 -0.024
202212 -0.030 121.477 -0.031
202303 -2.240 123.148 -2.299
202306 7.158 124.170 7.286
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast  (FRA:LWB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mesoblast Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Mesoblast's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (FRA:LWB) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Mesoblast (FRA:LWB) Headlines

No Headlines